

# Julio Cesar Teixeira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2864009/publications.pdf>

Version: 2024-02-01

62  
papers

5,905  
citations

304602

22  
h-index

149623

56  
g-index

63  
all docs

63  
docs citations

63  
times ranked

4551  
citing authors

#	ARTICLE	IF	CITATIONS
1	Organization of cervical cancer screening with DNA HPV testing impact on early stage cancer detection: a population based demonstration study in a Brazilian city. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100084.	1.5	9
2	The value of the endocervical margin status in LEEP: analysis of 610 cases. <i>Archives of Gynecology and Obstetrics</i> , 2022, , .	0.8	0
3	Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 264-271.	0.3	4
4	Maternal Deaths from COVID-19 in Brazil: Increase during the Second Wave of the Pandemic. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 567-572.	0.3	3
5	Human papillomavirus vaccination for adult women. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 631-635.	0.3	0
6	Safety of Conservative Management of High-Grade Squamous Intraepithelial Lesion in Women Under 30 Years Old. <i>Women S Health Reports</i> , 2022, 3, 601-607.	0.4	1
7	Cervical cancer in women under 25 years of age and outside the screening age: Diagnosis profile and long term outcomes. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 150-156.	1.0	6
8	Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 160, 379-383.	0.6	7
9	Elimination of cervical cancer in low and middle income countries: Inequality of access and fragile healthcare systems. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 7-11.	1.0	23
10	Malignant Uterine Neoplasms Attended at a Brazilian Regional Hospital: 16-years Profile and Time Elapsed for Diagnosis and Treatment. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 137-144.	0.3	1
11	Vaccination in women with cancer. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 150-154.	0.3	0
12	Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. <i>PLoS ONE</i> , 2021, 16, e0251688.	1.1	18
13	Conservative treatment of microinvasive squamous cell carcinoma of the cervix stage IA1: Defining conization height to an optimal oncological outcome. <i>PLoS ONE</i> , 2021, 16, e0253998.	1.1	3
14	Mortality in pregnancy and the postpartum period in women with severe acute respiratory distress syndrome related to COVID-19 in Brazil, 2020. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 475-482.	1.0	24
15	Is Diagnostic Hysteroscopy Safe for the Investigation of Type II Endometrial Cancer? A Retrospective Cohort Analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1536-1543.	0.3	11
16	HPV Vaccination and Screening with High-Performance Test: Brazilian Evidence. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 885-886.	0.3	1
17	School-based HPV Vaccination: The Challenges in a Brazilian Initiative. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 926-931.	0.3	7
18	Compulsory Vaccination: The Limit between Public and Private. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 785-786.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. <i>BMC Public Health</i> , 2020, 20, 576.	1.2	15
20	Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases. <i>Molecular and Clinical Oncology</i> , 2020, 13, 81.	0.4	5
21	Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 92.	0.4	0
22	Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	8
23	HPV Vaccines: Separating Myths from Reality. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2019, 41, 417-418.	0.3	3
24	Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas, Brazil. <i>BMC Public Health</i> , 2019, 19, 1492.	1.2	8
25	Systematic lymphadenectomy for intermediate risk endometrial carcinoma treatment does not improve the oncological outcome. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology</i> : X, 2019, 3, 100020.	0.6	9
26	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. <i>Sexually Transmitted Diseases</i> , 2019, 46, 663-669.	0.8	10
27	Use of interstitial brachytherapy in pelvic recurrence of cervical carcinoma: Clinical response, survival, and toxicity. <i>Brachytherapy</i> , 2019, 18, 146-153.	0.2	11
28	Incidence rates and temporal trends of cervical cancer relating to opportunistic screening in two developed metropolitan regions of Brazil: a population-based cohort study. <i>Sao Paulo Medical Journal</i> , 2019, 137, 322-328.	0.4	3
29	Stage and histology of cervical cancer in women under 25 years old. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e55.	1.0	4
30	Cervical Cancer Registered in Two Developed Regions from Brazil: Upper Limit of Reachable Results from Opportunistic Screening. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2018, 40, 347-353.	0.3	15
31	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	3.0	43
32	Analysis of Conservative Surgical Treatment and Prognosis of Microinvasive Squamous Cell Carcinoma of the Cervix Stage IA1: Results of Follow-Up to 20 Years. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 357-363.	1.2	18
33	Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2017, 39, 408-414.	0.3	0
34	Endocervical gastric-type adenocarcinoma, an unrelated HPV tumour: difficulties in screening and diagnosis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219724.	0.2	4
35	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. <i>BMJ Open</i> , 2016, 6, e011371.	0.8	34
36	Organized, Population-based Cervical Cancer Screening Program: It Would Be a Good Time for Brazil Now. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2016, 38, 161-163.	0.3	11

#	ARTICLE	IF	CITATIONS
37	Prior human papillomavirus 16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: <i>Post Hoc</i> analysis from a randomized controlled trial. <i>International Journal of Cancer</i> , 2016, 139, 2812-2826.	2.3	74
38	Development of a Multiplex PCR Test with Automated Genotyping Targeting E7 for Detection of Six High-Risk Human Papillomaviruses. <i>PLoS ONE</i> , 2015, 10, e0130226.	1.1	6
39	<i>Post Hoc</i> Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA. <i>Vaccine Journal</i> , 2015, 22, 235-244.	3.2	16
40	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	5.1	247
41	Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. <i>Vaccine Journal</i> , 2015, 22, 361-373.	3.2	89
42	MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical Lesions and Genital Infection by Human Papillomavirus and <i>Chlamydia trachomatis</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1539-1547.	1.1	28
43	Estudo do impacto das deficiências de saneamento básico sobre a saúde pública no Brasil no período de 2001 a 2009. <i>Engenharia Sanitaria E Ambiental</i> , 2014, 19, 87-96.	0.1	23
44	Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. <i>Journal of Infectious Diseases</i> , 2014, 210, 517-534.	1.9	45
45	Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. <i>BMC Infectious Diseases</i> , 2014, 14, 551.	1.3	32
46	Microinvasive Adenocarcinoma of the Cervix in a Young Woman Vaccinated Against Human Papillomavirus. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, E50-E54.	0.9	2
47	Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2147-2162.	1.4	207
48	Concomitant Cisplatin Plus Radiotherapy and High-Dose-Rate Brachytherapy Versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 542-547.	0.8	34
49	Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized) $T_j ETQq1 1.0.784314 rgBT / 1.9 73$	1.9	73
50	Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. <i>PLoS ONE</i> , 2013, 8, e79260.	1.1	101
51	Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 390-397.	1.4	168
52	Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. <i>Lancet Oncology</i> , The, 2012, 13, 89-99.	5.1	584
53	Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. <i>Lancet Oncology</i> , The, 2012, 13, 100-110.	5.1	432
54	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. <i>Gynecologic Oncology</i> , 2012, 127, 440-450.	0.6	55

#	ARTICLE	IF	CITATIONS
55	Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancer, 2012, 131, 106-116.	2.3	109
56	Prevalence of Human Papillomavirus Infection and Associated Risk Factors in Young Women in Brazil, Canada, and the United States. International Journal of Gynecological Pathology, 2011, 30, 173-184.	0.9	35
57	Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity. Revista Da Associação Médica Brasileira, 2010, 56, 37-40.	0.3	7
58	Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, The, 2009, 374, 301-314.	6.3	1,435
59	Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet, The, 2009, 374, 1975-1985.	6.3	328
60	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, The, 2004, 364, 1757-1765.	6.3	1,435
61	Primary melanoma of the uterine cervix figo stage III B. Sao Paulo Medical Journal, 1998, 116, 1778-1780.	0.4	7
62	Cervical cancer in women under 25 years old registered in a regional referral hospital: an 18-year evolutive analysis. , 0, , .		0